Status:
COMPLETED
IRAPe, Irisin and IL-34 in Patients With Type 2 Diabetes
Lead Sponsor:
Damanhour University
Collaborating Sponsors:
Tanta University
Conditions:
Type2 Diabetes Mellitus
Eligibility:
All Genders
35-65 years
Brief Summary
Aim: This study aimed to evaluate the role of extracellular part of insulin regulated aminopeptidase (IRAPe), IL-34, Irisin, and Visfatin in the development of insulin resistance in patients with type...
Detailed Description
Aim: This study aimed to evaluate the role of extracellular part of insulin regulated aminopeptidase (IRAPe), IL-34, Irisin, and Visfatin in the development of insulin resistance in patients with type...
Eligibility Criteria
Inclusion
- newly diagnosed type 2 diabetes and non-diabetic control subjects from 35 to 65 years old were enrolled in this study.
Exclusion
- individuals with inflammatory diseases, Cushing's syndrome, thyroid disorders, infectious diseases, cancers, hepatic diseases and renal impairment. Subjects on insulin or other medications that could affect glucose metabolism or pro-inflammatory cytokines assessment (Glucocorticoids, beta-Adrenergic agonists, Thiazides, etc.....) were also excluded from study
Key Trial Info
Start Date :
January 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 20 2019
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04107259
Start Date
January 19 2019
End Date
July 20 2019
Last Update
July 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527